Century Therapeutics (IPSC) Gains from Sales and Divestitures (2021 - 2026)
Century Therapeutics (IPSC) reported Gains from Sales and Divestitures of $441965.0 for Q1 2026, down 8.72% year-over-year from $484190.0 in Q1 2025, and up 1680.61% on a QoQ basis from $24821.0 in Q4 2025.
Century Therapeutics (IPSC) has 6 years of Gains from Sales and Divestitures data on file, last reported at $441965.0 in Q1 2026.
- Quarterly Gains from Sales and Divestitures fell 8.72% year-over-year to $441965.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $441965.0 (down 8.72% YoY) and the FY2025 annual result came in at $24821.0, down 98.34% from the prior year.
- Gains from Sales and Divestitures advanced to $441965.0 in Q1 2026 per IPSC's latest filing, from $24821.0 in the prior quarter.
- Across five years, Gains from Sales and Divestitures topped out at $1.5 million in Q4 2024 and bottomed at $24685.0 in Q1 2024.
- The 5-year median for Gains from Sales and Divestitures is $95877.0 (2023), against an average of $279124.2.
- Peak annual rise in Gains from Sales and Divestitures reached 1861.47% in 2025, while the deepest fall reached 98.34% in 2025.
- Tracing IPSC's Gains from Sales and Divestitures over 5 years: stood at $488758.0 in 2022, then tumbled by 80.38% to $95877.0 in 2023, then soared by 1461.5% to $1.5 million in 2024, then sank by 98.34% to $24821.0 in 2025, then soared by 1680.61% to $441965.0 in 2026.
- Per Business Quant, the three latest IPSC Gains from Sales and Divestitures figures stand at $441965.0 (Q1 2026), $24821.0 (Q4 2025), and $433168.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Century Therapeutics | 474.01 Mn | 474.01 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 441,965.00 |
| Mar 31, 2026 | 441,965.00 |
| Dec 31, 2025 | 24,821.00 |
| Dec 31, 2025 | 24,821.00 |
| Sep 30, 2025 | 433,168.00 |
| Sep 30, 2025 | 433,168.00 |
| Jun 30, 2025 | 24,734.00 |
| Jun 30, 2025 | 24,734.00 |
| Mar 31, 2025 | 484,190.00 |
| Mar 31, 2025 | 484,190.00 |
| Dec 31, 2024 | 1.50 Mn |
| Dec 31, 2024 | 1.50 Mn |
| Sep 30, 2024 | 24,731.00 |
| Sep 30, 2024 | 24,731.00 |
| Jun 30, 2024 | 24,685.00 |
| Jun 30, 2024 | 24,685.00 |
| Mar 31, 2024 | 24,685.00 |
| Mar 31, 2024 | 24,685.00 |
| Dec 31, 2023 | 95,877.00 |
| Dec 31, 2023 | 95,877.00 |
| Sep 30, 2023 | 95,877.00 |
| Sep 30, 2023 | 95,877.00 |
| Jun 30, 2023 | 95,877.00 |
| Jun 30, 2023 | 95,877.00 |
| Mar 31, 2023 | 95,877.00 |
| Mar 31, 2023 | 95,877.00 |
| Dec 31, 2022 | 488,758.00 |
| Dec 31, 2022 | 488,758.00 |
| Sep 30, 2022 | 434,009.00 |
| Sep 30, 2022 | 434,009.00 |
| Jun 30, 2022 | 297,583.00 |
| Jun 30, 2022 | 297,583.00 |
| Mar 31, 2022 | 161,159.00 |
| Mar 31, 2022 | 161,159.00 |
| Dec 31, 2021 | 566,033.00 |
| Dec 31, 2021 | 566,033.00 |
| Sep 30, 2021 | 429,608.00 |
| Sep 30, 2021 | 429,608.00 |
| Jun 30, 2021 | 281,262.00 |
| Jun 30, 2021 | 281,262.00 |